Skip to main content

NanoString Technologies Releases Fourth Quarter and Full Year 2022 Operating Results and Provides 2023 Financial Outlook

- Generated Record Orders for Over 105 Spatial Biology Instruments, Representing 50% Growth Year-over-Year -

- Q4 Revenue Over $34 Million -

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

“We are thrilled with the momentum that’s building in the spatial biology market. In 2022, we grew spatial biology instrument orders 50% year-on-year, and with approximately $40 million of CosMx orders in backlog, we are well-positioned for strong revenue growth in 2023,” said Brad Gray, President and CEO of NanoString. “At the Advances in Genome Biology and Technology (AGBT) conference earlier this month, we wowed researchers with demonstrations of our AtoMx Spatial Informatics Platform and customer-generated data using our new 6,000-plex CosMx RNA panel. We believe that we currently offer researchers the most compelling portfolio of spatial biology solutions, and with CosMx RNA assays that provide 12 times the data of competing platforms, and the only cloud-based spatial informatics suite, our lead is growing.”

Fourth Quarter Financial Highlights

  • Revenue of $34.4 million
  • Spatial biology revenue of $14.8 million
  • nCounter® revenue, inclusive of all service and other revenue, of $19.6 million

Full Year Financial Highlights

  • Revenue of $127.3 million
  • Spatial biology revenue of $44.7 million
  • nCounter revenue, inclusive of all service and other revenue, of $82.6 million
  • Cash, cash equivalents and short-term investments balance of $196.5 million as of December 31, 2022

Spatial Biology

  • Generated over 105 new system orders in Q4, including approximately 80 for CosMx™ and over 25 for GeoMx®
  • Shipped our first 13 CosMx systems in Q4, generating Q4 revenue of approximately $3 million
  • Exited 2022 with over 165 CosMx systems in backlog to be shipped in future periods, representing revenue to be recognized in future periods of approximately $40 million
  • Announced and demonstrated expansion of capability of CosMx to 6000-plex RNA at the 2023 AGBT annual conference, representing 12 times the number of data points per cell that can be analyzed as compared to competing spatial imaging platforms
  • Entered a collaboration with Weill Cornell Medical to create a Spatial Atlas of Human Anatomy (SAHA), that will create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults
  • Released CosMx SMI dataset generated from formalin-fixed paraffin-embedded (FFPE) human liver samples. The dataset highlights the data quality of the platform, demonstrating high sensitivity and high specificity capabilities
  • Total installed base of our spatial biology platforms of approximately 350, an increase of approximately 37% as compared to 2021
  • Total peer-reviewed publications featuring our spatial biology platforms were approximately 195 as of December 31, 2022, representing an increase of approximately 105 publications in the last 12 months

nCounter

  • Total installed base of our nCounter platforms of approximately 1,120, an increase of approximately 7% as compared to 2021
  • Total peer-reviewed publications featuring nCounter were approximately 6,520 as of December 31, 2022, representing an increase of approximately 1,320 publications in the last 12 months

2023 Outlook

The company, based on its plans and initiatives for 2023, expects to record results approximately as follows:

  • Revenue of $170 to $180 million, including spatial biology revenue of $95 to $100 million and nCounter revenue, inclusive of all service and other revenue, of $75 to $80 million
  • Adjusted EBITDA loss of $65 to $75 million

Financial Results

We have elected to present selected non-GAAP, or adjusted, financial measures, including Adjusted EBITDA. These adjusted financial measures are calculated excluding certain items that may make it more challenging to compare our GAAP operating results across periods. Such items may include collaboration revenue, stock-based compensation, depreciation and amortization, or one-time charges such as transaction related fees and expenses or restructuring charges and severance costs. A reconciliation of adjusted financial measures to the nearest comparable GAAP financial measure can be found in the tables at the end of this press release.

(dollars in thousands)

Three Months Ended December 31,

 

GAAP

 

Non-GAAP Adjusted

 

2022

 

2021

 

2022

 

2021

Total revenue

$

34,422

 

 

$

42,455

 

 

$

34,420

 

 

$

42,007

 

Cost of revenue

 

21,122

 

 

 

20,046

 

 

 

19,604

 

 

 

19,394

 

Gross margin

 

39

%

 

 

53

%

 

 

43

%

 

 

54

%

Research and development

 

19,086

 

 

 

18,162

 

 

 

14,996

 

 

 

15,693

 

Selling, general and administrative

 

36,895

 

 

 

31,596

 

 

 

27,530

 

 

 

26,553

 

Adjusted EBITDA

 

N / A

 

 

N / A

 

$

(27,710

)

 

$

(19,633

)

 

 

 

 

 

 

 

 

Non-operating expense, net

 

(1,433

)

 

 

(1,912

)

 

 

(1,433

)

 

 

(1,912

)

Net loss

$

(44,114

)

 

$

(29,261

)

 

$

(29,143

)

 

$

(21,545

)

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

GAAP

 

Non-GAAP Adjusted

 

2022

 

2021

 

2022

 

2021

Total revenue

$

127,262

 

 

$

145,085

 

 

$

126,725

 

 

$

143,957

 

Cost of revenue

 

65,475

 

 

 

68,304

 

 

 

60,721

 

 

 

65,502

 

Gross margin

 

49

%

 

 

53

%

 

 

52

%

 

 

54

%

Research and development

 

70,841

 

 

 

69,504

 

 

 

58,968

 

 

 

59,301

 

Selling, general and administrative

 

143,129

 

 

 

115,503

 

 

 

115,593

 

 

 

92,985

 

Adjusted EBITDA

 

N / A

 

 

N / A

 

$

(108,557

)

 

$

(73,831

)

 

 

 

 

 

 

 

 

Non-operating expense, net

 

(7,360

)

 

 

(7,028

)

 

 

(7,360

)

 

 

(7,028

)

Net loss

$

(159,543

)

 

$

(115,254

)

 

$

(115,917

)

 

$

(80,859

)

Supplemental Information

As a supplement to the table above, we have posted to the investor relations section of our website, at https://investors.nanostring.com/financials/quarterly-results/default.aspx, supplemental financial data that include our adjusted financial measures as compared to the nearest comparable GAAP financial measures, for the fourth quarter and full year of 2022 and for each quarter of and the full year of 2021.

Conference Call

Management will host a conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Investors and other interested parties can register for the call in advance by visiting https://investors.nanostring.com/events-and-presentations/default.aspx. After registering, an email confirmation will be sent including dial-in details and unique conference call codes for entry. Registration is open throughout the call, but to ensure connection for the full call, registration in advance is recommended. The link to the webcast and audio replay will be made available at the Investor Relations website: www.nanostring.com. A replay of the call will be available beginning February 28, 2023 at 7:30 pm ET through midnight ET on March 14, 2023. To access the replay, dial (866) 813-9403 or (929) 458-6194 and reference Conference ID: 176735. The webcast will also be available on our website for one year following the completion of the call.

Non-GAAP, or Adjusted, Financial Information

We believe that the presentation of non-GAAP, or adjusted, financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Reconciliation of adjusted financial measures to the most directly comparable financial result as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. For further information regarding why we believe that these adjusted measures provide useful information to investors, the specific manner in which management uses these measures and some of the limitations associated with the use of these measures, please refer to “Notes Regarding Non-GAAP Financial Information” at the end of this press release.

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in approximately 190 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, cited in approximately 6,520 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, future revenue growth, future operating results, future cash flows, the impact of new products and expansion into new markets, the growth trajectory of our nCounter, GeoMx and CosMx franchises, and our estimated 2023 operating results and our anticipated GAAP and non-GAAP operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, AtoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

NANOSTRING TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

Three Months Ended

December 31,

 

Years Ended December 31,

 

2022

 

2021

 

2022

 

2021

Revenue:

 

 

 

 

 

 

 

Instruments

$

10,925

 

 

$

17,560

 

 

$

37,589

 

 

$

55,616

 

Consumables

 

18,470

 

 

 

19,874

 

 

 

70,367

 

 

 

71,846

 

Services and other

 

5,027

 

 

 

5,021

 

 

 

19,306

 

 

 

17,623

 

Total revenue

 

34,422

 

 

 

42,455

 

 

 

127,262

 

 

 

145,085

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenue

 

21,122

 

 

 

20,046

 

 

 

65,475

 

 

 

68,304

 

Research and development

 

19,086

 

 

 

18,162

 

 

 

70,841

 

 

 

69,504

 

Selling, general and administrative

 

36,895

 

 

 

31,596

 

 

 

143,129

 

 

 

115,503

 

Total costs and expenses (a) (b)

 

77,103

 

 

 

69,804

 

 

 

279,445

 

 

 

253,311

 

Loss from operations

 

(42,681

)

 

 

(27,349

)

 

 

(152,183

)

 

 

(108,226

)

Other income (expense):

 

 

 

 

 

 

 

Interest income

 

1,078

 

 

 

147

 

 

 

2,409

 

 

 

649

 

Interest expense

 

(1,885

)

 

 

(1,876

)

 

 

(7,535

)

 

 

(7,490

)

Other income expense, net

 

(631

)

 

 

(99

)

 

 

(1,917

)

 

 

(20

)

Total other expense, net

 

(1,438

)

 

 

(1,828

)

 

 

(7,043

)

 

 

(6,861

)

Net loss before provision for income taxes

 

(44,119

)

 

 

(29,177

)

 

 

(159,226

)

 

 

(115,087

)

Provision for income taxes

 

5

 

 

 

(84

)

 

 

(317

)

 

 

(167

)

Net loss

$

(44,114

)

 

$

(29,261

)

 

$

(159,543

)

 

$

(115,254

)

Net loss per share, basic and diluted

$

(0.95

)

 

$

(0.64

)

 

$

(3.44

)

 

$

(2.54

)

Weighted average shares used in computing basic and diluted net loss per share

 

46,663

 

 

 

45,682

 

 

 

46,406

 

 

 

45,299

 

 

 

 

 

 

 

 

 

(a) Includes $6.3 million and $6.5 million of stock-based compensation expense for the three month period ended December 31, 2022, and 2021, respectively, and $25.9 million and $30.2 million for the twelve months ended December 31, 2022 and 2021, respectively.

(b) Includes $3.0 million and $1.5 million of depreciation and amortization expense for the three month period ended December 31, 2022 and 2021, respectively, and $8.1 million and $5.9 million for the twelve months ended December 31, 2022 and 2021, respectively.

NANOSTRING TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 

December 31,

 

2022

 

2021

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

112,250

 

$

107,068

Restricted cash and equivalents

 

898

 

 

 

 

Short-term investments

 

84,282

 

 

 

241,821

 

Accounts receivable, net

 

31,506

 

 

 

40,130

 

Inventory, net

 

43,273

 

 

 

31,486

 

Prepaid expenses and other

 

14,565

 

 

 

7,115

 

Total current assets

 

286,774

 

 

 

427,620

 

Property and equipment, net

 

44,457

 

 

 

27,043

 

Operating lease right-of-use assets

 

17,581

 

 

 

19,226

 

Other assets

 

4,600

 

 

 

5,592

 

Total assets

$

353,412

 

 

$

479,481

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

16,619

 

 

$

14,283

 

Accrued liabilities

 

7,884

 

 

 

6,765

 

Accrued compensation and other employee benefits

 

17,494

 

 

 

17,466

 

Customer deposits

 

1,757

 

 

 

1,278

 

Deferred revenue and other liabilities, current portion

 

9,588

 

 

 

7,474

 

Operating lease liabilities, current portion

 

5,518

 

 

 

4,889

 

Total current liabilities

 

58,860

 

 

 

52,155

 

Deferred revenue and other liabilities, net of current portion

 

3,754

 

 

 

3,527

 

Long-term debt, net

 

226,622

 

 

 

225,144

 

Operating lease liabilities, net of current portion

 

18,362

 

 

 

21,693

 

Total liabilities

 

307,598

 

 

 

302,519

 

Total stockholders’ equity

 

45,814

 

 

 

176,962

 

Total liabilities and stockholders’ equity

$

353,412

 

 

$

479,481

 

Notes Regarding Non-GAAP Financial Information. In addition to our results reported in accordance with U.S. generally accepted accounting principles (“GAAP”), we believe certain non-GAAP, or adjusted, measures are useful in evaluating our operating performance. We use adjusted financial measures to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that adjusted financial measures, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, adjusted financial information has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In particular, other companies, including companies in our industry, may calculate similarly titled non-GAAP or adjusted measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our adjusted financial measures as tools for comparison. A reconciliation is provided below for adjusted financial measures to the most directly comparable financial measure stated in accordance with U.S. GAAP. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP, or adjusted, financial measures as analytical tools. Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these adjusted financial measures to their most directly comparable U.S. GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

Expenses excluded from non-GAAP, or adjusted, total revenue, cost of revenue, research and development expense and selling, general and administrative expense and net loss. We exclude stock-based compensation expense, impairment expense and depreciation and amortization expense, which are non-cash expenses, from certain of our adjusted financial measures because we believe that excluding such items provides meaningful supplemental information regarding operational performance. We exclude certain expenses related to reorganization and restructuring charges, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses from certain of our adjusted financial measures because such expenses have no direct correlation to the continuing operation of our business as such expenses are non-recurring or non-operating in nature, and therefore we believe excluding these items provides meaningful supplemental information regarding operational performance.

Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure defined as GAAP net loss adjusted for collaboration revenue, stock-based compensation expense, impairment expense, depreciation and amortization, net interest expense, other non-operating expense or income, provision for income tax and other special items as determined by management, including certain expenses related to reorganization and restructuring charges, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses.

The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands).

 

Three Months Ended

December 31,

 

Years Ended December 31,

 

2022

 

2021

 

2022

 

2021

Net loss - GAAP

$

(44,114

)

 

$

(29,261

)

 

$

(159,543

)

 

$

(115,254

)

Collaboration revenue

 

(2

)

 

 

(448

)

 

 

(537

)

 

 

(1,128

)

Stock-based compensation

 

6,264

 

 

 

6,484

 

 

 

25,908

 

 

 

30,173

 

Depreciation and amortization

 

2,965

 

 

 

1,524

 

 

 

8,116

 

 

 

5,871

 

Interest expense, net

 

807

 

 

 

1,729

 

 

 

5,126

 

 

 

6,841

 

Other expense, net

 

631

 

 

 

99

 

 

 

1,917

 

 

 

20

 

Provision for income taxes

 

(5

)

 

 

84

 

 

 

317

 

 

 

167

 

Reorganization and restructuring charges

 

2,384

 

 

 

 

 

 

2,384

 

 

 

 

Other business development expense

 

 

 

 

 

 

 

393

 

 

 

115

 

Litigation expense

 

2,387

 

 

 

 

 

 

5,921

 

 

 

 

Impairment expense

 

823

 

 

 

 

 

 

823

 

 

 

 

Recovery of certain previously remitted state and local taxes

 

 

 

 

 

 

 

 

 

 

(896

)

Cloud computing arrangement implementation expense

 

150

 

 

 

156

 

 

 

618

 

 

 

260

 

Adjusted EBITDA - non-GAAP

 

(27,710

)

 

 

(19,633

)

 

 

(108,557

)

 

 

(73,831

)

Non-operating expense, net

 

(1,433

)

 

 

(1,912

)

 

 

(7,360

)

 

 

(7,028

)

Net loss - non-GAAP

$

(29,143

)

 

$

(21,545

)

 

$

(115,917

)

 

$

(80,859

)

 

Three Months Ended

December 31,

 

Years Ended December 31,

 

2022

 

2021

 

2022

 

2021

GAAP Total revenue

$

34,422

 

 

$

42,455

 

 

$

127,262

 

 

$

145,085

 

Collaboration revenue

 

(2

)

 

 

(448

)

 

 

(537

)

 

 

(1,128

)

Non-GAAP Total revenue

$

34,420

 

 

$

42,007

 

 

$

126,725

 

 

$

143,957

 

 

 

 

 

 

 

 

 

GAAP Cost of revenue

$

21,122

 

 

$

20,046

 

 

$

65,475

 

 

$

68,304

 

Stock-based compensation

 

(744

)

 

 

(469

)

 

 

(2,759

)

 

 

(2,125

)

Depreciation and amortization

 

(774

)

 

 

(183

)

 

 

(1,995

)

 

 

(677

)

Non-GAAP Cost of revenue

$

19,604

 

 

$

19,394

 

 

$

60,721

 

 

$

65,502

 

 

 

 

 

 

 

 

 

GAAP Gross margin

39%

 

53%

 

49%

 

53%

Non-GAAP Gross margin

43%

 

54%

 

52%

 

54%

 

 

 

 

 

 

 

 

GAAP Research and development

$

19,086

 

 

$

18,162

 

 

$

70,841

 

 

$

69,504

 

Stock-based compensation

 

(1,563

)

 

 

(1,543

)

 

 

(6,867

)

 

 

(6,182

)

Reorganization and restructuring charges

 

(881

)

 

 

 

 

 

(881

)

 

 

 

Depreciation and amortization

 

(1,646

)

 

 

(926

)

 

 

(4,125

)

 

 

(3,906

)

Other business development activities

 

 

 

 

 

 

 

 

 

 

(115

)

Non-GAAP Research and development

$

14,996

 

 

$

15,693

 

 

$

58,968

 

 

$

59,301

 

 

 

 

 

 

 

 

 

GAAP Selling, general and administrative

$

36,895

 

 

$

31,596

 

 

$

143,129

 

 

$

115,503

 

Stock-based compensation

 

(3,957

)

 

 

(4,472

)

 

 

(16,282

)

 

 

(21,866

)

Reorganization and restructuring charges

 

(1,503

)

 

 

 

 

 

(1,503

)

 

 

 

Depreciation and amortization

 

(545

)

 

 

(415

)

 

 

(1,996

)

 

 

(1,288

)

Other business development activities

 

 

 

 

 

 

 

(393

)

 

 

 

Litigation expenses

 

(2,387

)

 

 

 

 

 

(5,921

)

 

 

 

Impairment expenses

 

(823

)

 

 

 

 

 

(823

)

 

 

 

Recovery of certain previously remitted state and local taxes

 

 

 

 

 

 

 

 

 

 

896

 

Cloud computing arrangements implementation expense

 

(150

)

 

 

(156

)

 

 

(618

)

 

 

(260

)

Non-GAAP Selling, general and administrative

$

27,530

 

 

$

26,553

 

 

$

115,593

 

 

$

92,985

 

 

Contacts

Doug Farrell

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.